Sandoz completed the acquisition of CIMERLI business from Coherus for $170m.

Sandoz, a supplier of off-patent medicines, completed the acquisition of CIMERLI business from Coherus, a biopharmaceutical company, for $170m. “I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise. The addition of CIMERLI® reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the US,” Keren Haruvi, Sandoz North America President.